Results 61 to 70 of about 5,894 (144)

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B. [PDF]

open access: yesEClinicalMedicine
Röth A   +19 more
europepmc   +1 more source

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.

open access: yesBlood, 2019
Jäger U   +13 more
europepmc   +1 more source

The Complosome: An Emerging Intracellular Complement Network in Cancer Development and Therapy. [PDF]

open access: yesInt J Mol Sci
Zadroga Ł   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy